These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29383700)

  • 1. Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.
    Jiang H; Lwin T; Zhao X; Ren Y; Li G; Moscinski L; Shah B; Tao J
    Br J Haematol; 2019 Jan; 184(2):298-302. PubMed ID: 29383700
    [No Abstract]   [Full Text] [Related]  

  • 2. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
    Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
    N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ready, AIM, stop: ibrutinib plus venetoclax in MCL.
    Wallace DS; Barr PM
    Blood; 2024 Aug; 144(8):800-802. PubMed ID: 39172439
    [No Abstract]   [Full Text] [Related]  

  • 4. Hyperleukocytosis increases risk of fatal hyperkalemia with new ibrutinib/venetoclax regimen for refractory mantle cell lymphoma.
    Verma A; Mbughuni M; Mariash E; Mesa H
    J Chemother; 2019; 31(7-8):428-431. PubMed ID: 31738653
    [No Abstract]   [Full Text] [Related]  

  • 5. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.
    Hampel PJ; Call TG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Rabe KG; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
    Am J Hematol; 2020 Mar; 95(3):E57-E60. PubMed ID: 31788844
    [No Abstract]   [Full Text] [Related]  

  • 6. Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
    Handunnetti SM; Anderson MA; Burbury K; Thompson PA; Burke G; Bressel M; Di Iulio J; Hicks RJ; Westerman D; Lade S; Pott C; Agarwal R; Koldej R; Ritchie D; Dreyling M; Dawson MA; Dawson SJ; Seymour JF; Roberts AW; Tam CS
    Blood; 2024 Aug; 144(8):867-872. PubMed ID: 38662991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.
    Eyre TA; Walter HS; Iyengar S; Follows G; Cross M; Fox CP; Hodson A; Coats J; Narat S; Morley N; Dyer MJS; Collins GP
    Haematologica; 2019 Feb; 104(2):e68-e71. PubMed ID: 30190341
    [No Abstract]   [Full Text] [Related]  

  • 8. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
    Le Gouill S; Morschhauser F; Chiron D; Bouabdallah K; Cartron G; Casasnovas O; Bodet-Milin C; Ragot S; Bossard C; Nadal N; Herbaux C; Tessoulin B; Tchernonog E; Rossi C; McCulloch R; Gastinne T; Callanan MB; Rule S
    Blood; 2021 Feb; 137(7):877-887. PubMed ID: 33181832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted Agents.
    Wages NA; Portell CA; Williams ME; Conaway MR; Petroni GR
    Clin Cancer Res; 2017 Dec; 23(23):7158-7164. PubMed ID: 28733439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
    Tarantelli C; Zhang L; Curti E; Gaudio E; Spriano F; Priebe V; Cascione L; Arribas AJ; Zucca E; Rossi D; Stathis A; Bertoni F
    Haematologica; 2019 Jul; 104(7):e307-e309. PubMed ID: 30679329
    [No Abstract]   [Full Text] [Related]  

  • 11. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
    Wang M; Ramchandren R; Chen R; Karlin L; Chong G; Jurczak W; Wu KL; Bishton M; Collins GP; Eliadis P; Peyrade F; Lee Y; Eckert K; Neuenburg JK; Tam CS
    J Hematol Oncol; 2021 Oct; 14(1):179. PubMed ID: 34717692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.
    Srour SA; Lee HJ; Nomie K; Ye H; Chen W; Oriabure O; Romaguera J; Wang ML
    Br J Haematol; 2018 May; 181(4):561-564. PubMed ID: 28369820
    [No Abstract]   [Full Text] [Related]  

  • 13. Fatal splenic rupture after discontinuing treatment by ibrutinib and venetoclax in relapse/refractory mantle cell lymphoma.
    Roulin L; Haioun C; Lemonnier F
    Ann Hematol; 2021 May; 100(5):1345-1347. PubMed ID: 33655374
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
    Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
    Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm.
    Tremblay D; Feld J; Dougherty M; Czaplinska T; Sanchez G; Kremyanskaya M; Bar-Natan M; Shih AH; Keyzner A; Mascarenhas J
    Leuk Res; 2020 Nov; 98():106456. PubMed ID: 33002673
    [No Abstract]   [Full Text] [Related]  

  • 16. Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma.
    Zhou X; Steinhardt MJ; Düll J; Krummenast F; Danhof S; Meckel K; Nickel K; Grathwohl D; Leicht HB; Rosenwald A; Einsele H; Rasche L; Kortüm M
    Eur J Haematol; 2020 Apr; 104(4):352-355. PubMed ID: 31922303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.
    Parikh A; Gopalakrishnan S; Freise KJ; Verdugo ME; Menon RM; Mensing S; Salem AH
    Leuk Lymphoma; 2018 Apr; 59(4):871-879. PubMed ID: 28797193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
    Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Nishikawa T
    J Clin Exp Hematop; 2019; 59(2):98-100. PubMed ID: 31257351
    [No Abstract]   [Full Text] [Related]  

  • 19. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
    Thompson PA; Burger JA
    Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.